What We're Reading: Page 392
Industry reads hand-picked by our editors
Nov 17, 2014
-
Reuters
AstraZeneca in preclinical development for Brilinta reversal agent
-
-
Apollo Global Manangement joins bidding wars for GSK's mature drugs
-
-
FDA approves new Invega indication for schizoaffective disorder
-
-
Pfizer, Gates Foundation team up to get injectable contraceptives to poor countries
-
-
FDA has concerns over bioequivalence of two Concerta generics
-
Japanese transparency data raises eyebrows about pharma spending
Nov 14, 2014
-
-
Let's make a deal: Allergan, Actavis talk $60 billion merger
-
-
Gilead, AbbVie hep C drugs score 97% cure rates, Regulus gets cold shoulder
-
-
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
-
Indian pharma really feeling the pain of lagging US generic approvals
-
GSK applying for expanded Revolade indication in the EU
-
No more half measures: Senate to add Ebola to priority review program
-
Advaxis wants to investigate a compound for head & neck HPV-related cancers
Nov 13, 2014
-
10 major hospitals ask Congress to scrutinize Genentech distribution changes
-
-
Shire CEO: The future looks bright—who needs AbbVie?
-
-
-
Activist investor Bill Ackman's $2 billion fallback plan for Valeant
-
-
Does a common 'algae virus' found in humans really make them dumb?
-
GE Healthcare and Takeda to take on liver disease R&D together
-
Nov 12, 2014
-
Specter of antitrust charges looms as Justice Department probes generic price hikes
-
-
Swing and a miss: Merck's ambitious 4-week hep C regimen fails
-
-
Amgen gets PDUFA date for hotly anticipated PCSK9 anti-cholesterol drug
-
-
Pfizer: Nothing shady about our relationship with Missouri Attorney General
-
Cigna responds to discrimination claims with cheaper HIV meds in Florida
-
-
Best of BD: Is the current antibiotic pipeline really that bad? [INFOGRAPHIC]
Nov 11, 2014
-
The cost of a cure: $188B to treat all US hep C patients with pricey new drugs
-
-
Advocates slam protracted UK negotiations over Novartis meningitis B vaccine
-
Salix Pharmaceuticals' inventory woes ruined potential Allergan buyout
-
Political unrest in Russia nixes deal with German pharma company
-
-
-
-
Isis Pharma wins $10M neurodegeneration treatment milestone from Biogen
-
Nov 10, 2014
-
This billionaire hedge fund manager may sue over busted AbbVie-Shire deal
-
-
Ranbaxy loses $250M while US consumers lose a Nexium generic
-
-
FDA approves JNJ's Olysio in combo with Sovadi for hep C treatment
-
-
Allergan, Actavis talk merger while Valeant gets the cold shoulder
-
-
FDA sends Sciecure Pharma rare, scathing letter over insomnia drug sales aid
-
Nov 07, 2014
-
-
-
AZ's $2B ovarian cancer drug-in-development could be a 2-for-1 deal
-
-
-
Why GSK's promising hep C vaccine is good news for its Ebola drug
-
FDA presents novel plan for testing and fast-tracking Ebola drugs
-
-
Largest US pharma benefits manager may seek alcohol/tobacco-free network
-
AstraZeneca lifts 2014 forecast, but how will it deal with Nexium patent expiration?
Previous
